NCT04422457 is a NA clinical trial of 68Ga-DX600 PET/CT in Solid Tumor, sponsored by Peking University Cancer Hospital & Institute.

Who is sponsoring NCT04422457?

NCT04422457 is sponsored by Peking University Cancer Hospital & Institute.

What drugs are being tested in NCT04422457?

Interventions in NCT04422457: 68Ga-DX600 PET/CT.

What condition does NCT04422457 study?

NCT04422457 studies Solid Tumor.

Is NCT04422457 still recruiting?

NCT04422457 is currently completed. Last updated 19 August 2024.

Last reviewed 2024-08-19 · How we verify

NCT04422457

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Specific Molecular Imaging of DX600 Labeled by PET Radionuclide Targeting ACE2 in Patients

Completed NA Last updated 19 August 2024

What this trial tests

NA trial testing 68Ga-DX600 PET/CT in Solid Tumor in 30 participants. Completed in 1 March 2022.

Timeline

13 June 2020

Primary endpoint
1 March 2022

1 March 2022

Quick facts

Lead sponsor	Peking University Cancer Hospital & Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	30
Start date	13 June 2020
Primary completion	1 March 2022
Estimated completion	1 March 2022
Sites	1 location across China

Drugs / interventions tested

68Ga-DX600 PET/CT

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

Peking University Cancer Hospital & Institute

Who can join

Adults 18 to 75, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Angiotensin-converting enzyme 2 (ACE2) plays an important role in renin-angiotensin system (RAS) and has been reported to relate with cancer. Recently, it has also been proved as the key target for COVID-19 infection. DX600 is a polypeptide that can specific binding to ACE2 specifically with nanomolar affinity reported in literature. This study constrcuted a radio-tracer, DX600 Labeled by PET Radionuclide, to monitoring biodistribution ACE2 in human beings, evaluate the detection ability of radio-tracer in ACE2 over-expression tumors and dynamic changes of ACE2 expression under therapy.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular PET/CT Profiling of ACE2 Expression In Vivo: Implications for Infection and Outcome from SARS-CoV-2.
Zhu H, Zhang H, Zhou N, Ding J, et al · · 2021 · cited 26× · PMID 34174177 · DOI 10.1002/advs.202100965
Molecular Imaging of ACE2 Expression in Infectious Disease and Cancer.
Li Z, Hasson A, Daggumati L, Zhang H, et al · · 2023 · cited 3× · PMID 37896761 · DOI 10.3390/v15101982
Radiotracers for Molecular Imaging of Angiotensin-Converting Enzyme 2.
Xu W, Langhans SA, Johnson DK, Stauff E, et al · · 2024 · cited 2× · PMID 39273366 · DOI 10.3390/ijms25179419

Verify or expand the search:

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other Peking University Cancer Hospital & Institute trials

Trials by the same sponsor.

NCT07527806 — Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Im · Phase 2 · not yet recruiting
NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
NCT07417241 — SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study · Phase 2 · not yet recruiting
NCT07470203 — Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer · not yet recruiting
NCT07394192 — Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-I · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04422457 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University Cancer Hospital & Institute
Last refreshed: 19 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04422457.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing